Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-08-12
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. It is not yet known whether
giving cetuximab together with carboplatin is more effective than giving cetuximab alone in
treating metastatic breast cancer.
PURPOSE: This randomized phase II trial is studying cetuximab and carboplatin to see how well
they work compared with cetuximab alone in treating women with estrogen receptor-negative
(ER-), progesterone receptor-negative (PR-) metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Avon Foundation Bristol-Myers Squibb National Cancer Institute (NCI) National Center for Research Resources (NCRR)